Ackman: Valeant Can Sell Non-Core Assets to Reduce Debt

(Editor's note: This article originally appeared at 2:54 p.m. ET on Nov. 10 on Real Money, our premium site for active traders. To get great columns like this from Jim Cramer and other top columnists earlier in the trading day, click here.)

Many investors have all but lost hope that Valeant Pharmaceuticals  (VRX)  can find its way out of its $30 billion debt swamp. But billionaire activist Bill Ackman, a Valeant board member, says there's an exit strategy that can even leave a hefty pile of cash on the books. 

There are several ways for Valeant, which Ackman views as substantially undervalued, to extricate itself from its debt problems, he said on a Thursday teleconference with investors of his Pershing Square hedge fund.

"I don't think the world will look at this company on a sum-of-the-parts basis until it has a more conservative balance sheet," he said. "And to that end, the company has an asset-disposition program that is under way."

By selling assets deemed "non-core" to its central business model, Valeant is likely to rope in more than $8 billion of cash, Ackman said, and proceeds from selling its Salix businesses -- which control Valeant's key stomach drug, Xifaxan -- could pull in about $8.5 billion in cash and another $1.5 billion in royalties, according to recent reports by Dow Jones and The Wall Street Journal.

"Think about Valeant in a world in which it sold half or all its noncore assets, plus Salix," Ackman noted. "it could pay off all its bank debt, have significant net cash, would own a mix of businesses that would be of a disproportionately higher nature."

If you liked this article you might like

ADP Is Morphing Into the IBM Blob: Bill Ackman

Follow the Crucial '$20 Level Rule' When Trading Stocks

$20 Should Be Your Cutoff Point

Short the Stocks That Fall Below $20

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year